Ferring Agrees to Buy Fertility Biotech Gameto

Ferring and Gameto Reach Acquisition Agreement

Ferring has agreed to buy fertility biotech Gameto for up to USD 1.38bn, Medwatch reported. The reported value includes amounts that depend on Gameto reaching development, regulatory and sales milestones.

The agreement puts the structure of the transaction alongside milestones that remain to be achieved. Medwatch identified development, regulatory and sales outcomes as elements that will determine part of the deal value.

FDA Approval Still Required for Lead Technology

Gameto’s lead technology still needs FDA approval, according to Medwatch. The FDA approval requirement is among the regulatory considerations surrounding the company as Ferring moves forward with the agreement to buy Gameto.

For pharmaceutical and biotechnology sales professionals tracking fertility-focused companies, the report places the acquisition agreement and Gameto’s regulatory status in the same update. Medwatch reported both that Ferring agreed to buy Gameto and that the company’s lead technology still requires FDA approval.

Milestones Shape Part of the Reported Value

Medwatch said the deal is valued at up to USD 1.38bn. Part of that value depends on development, regulatory and sales milestones being reached.

• Ferring agreed to buy Gameto, Medwatch reported.
• The deal is valued at up to USD 1.38bn.
• Part of the value depends on development, regulatory and sales milestones.
• Gameto’s lead technology still needs FDA approval.

The reported agreement centers on a fertility biotech company whose lead technology remains subject to FDA approval. Medwatch’s account also makes clear that the full value described for the transaction is linked in part to the specified milestones.